Skip to main content

Table 4 Response, remission, recovery, and study discontinuation

From: Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study

  Placebo Olanzapine p Value
  (n = 52) (n = 104)  
  n (%) n (%)  
Response 21 (40.4) 57 (54.8) .13
Partial remission (MADRS ≤12) 29 (55.8) 56 (53.8) .87
Full remission (MADRS ≤8) 18 (34.6) 45 (43.3) .39
Recovery 5 (9.6) 15 (14.4) .46
Study discontinuations    
 Total 11 (21.2) 18 (17.3) .66
 Due to adverse events 4 (7.7) 10 (9.6) .78
 Due to lack of efficacy 1 (1.9) 0 (0.0) .33
 Lost to follow-up 0 (0.0) 1 (1.0) 1.00
  1. Abbreviations: MADRS = Montgomery-Åsberg Depression Rating Scale.
\